NCT01595399

Brief Summary

The purpose of this study is to compare heart rate in infants who receive atropine as a part of their medication before intubation to those who do not. To be able to find out , we need to divided babies into 2 groups; group 1 : receives atropine + sedation + muscle relaxant group 2 : receives water or saline ( placebo group) + sedation + muscle relaxant Then we need to compare heart rate during intubation and duration of intubation between the 2 groups.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Apr 2012

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 8, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 10, 2012

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

September 24, 2013

Status Verified

May 1, 2012

Enrollment Period

2.2 years

First QC Date

May 8, 2012

Last Update Submit

September 23, 2013

Conditions

Keywords

bradycardiahypoxemiaintubationpremedication

Outcome Measures

Primary Outcomes (1)

  • Heart rate less than 80 BPM and oxygen saturation less than 80%

    Heart rate and transcutaneous oxygen saturation will be monitored continuously during the procedure and data will be recorded at 3 stages; 1. 2 minutes prior to intubation (after atropine or placebo dose) 2. during intubation 3. 2 minutes after intubation (once ETT secured to face)

    5-6 minutes

Secondary Outcomes (6)

  • Heart rate < 100 BPM

    5-6 minutes

  • Oxygen saturation < 85%

    5-6 minutes

  • Duration of intubation attempts

    1-2 minutes

  • Number of intubation attempts

    5-6 minutes

  • Lowest heart rate after premedication

    5-6 minutes

  • +1 more secondary outcomes

Study Arms (2)

Atropine, fentanyl and succinylcholine

ACTIVE COMPARATOR

20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.

Drug: atropine

placebo, fentanyl and succinylcholine

PLACEBO COMPARATOR

an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.

Drug: Placebo

Interventions

Atropine 0.02 mg/kg IV

Also known as: AtroPen
Atropine, fentanyl and succinylcholine

an equivalent volume of normal saline to atropine IV

Also known as: 0.9% sodium chloride
placebo, fentanyl and succinylcholine

Eligibility Criteria

Age1 Day - 2 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Any infant (preterm and term) up to 46 weeks corrected age requiring (nonemergent) intubation.
  • IV access is obtained
  • Informed parental consent

You may not qualify if:

  • Emergent intubation or need for resuscitation
  • Congenital cyanotic heart disease
  • Obvious airway abnormalities
  • History of myopathy or family history of malignant hyperthermia or known history of phosphocholinesterase deficiency

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Health Sciences Centre

Winnipeg, Manitoba, R3A1R9, Canada

RECRUITING

Related Publications (1)

  • Afifi J, El-Naggar W, Hatfield T, Sandila N, Baier J, Narvey M. Atropine Versus Placebo for Neonatal Nonemergent Intubation: A Randomized Clinical Trial. J Pediatr. 2025 Nov;286:114719. doi: 10.1016/j.jpeds.2025.114719. Epub 2025 Jul 9.

MeSH Terms

Conditions

BradycardiaHypoxia

Interventions

AtropineSodium Chloride

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms, RespiratorySigns and Symptoms

Intervention Hierarchy (Ancestors)

Atropine DerivativesTropanesAzabicyclo CompoundsAza CompoundsOrganic ChemicalsBelladonna AlkaloidsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-RingChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Michael R Narvey, MD

    University of Manitoba

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michael R Narvey, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 8, 2012

First Posted

May 10, 2012

Study Start

April 1, 2012

Primary Completion

June 1, 2014

Study Completion

June 1, 2014

Last Updated

September 24, 2013

Record last verified: 2012-05

Locations